PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Single and Multiple Dose Study of PF-05221304 in Healthy Japanese Adults

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-05221304
Drug: Placebo

First Posted Date: 2018-07-24

Last Posted Date: 2018-11-27

Lead Sponsor: Pfizer

Target Recruit Count: 15

Registration Number: NCT03597217

Locations: 🇯🇵
P-one Clinic, Keikokai Medical Corporation, Hachioji-shi, Tokyo, Japan

Drug-Drug Interaction Study to Evaluate the Effect of PF-06865571 on Metformin Pharmacokinetics

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Metformin
Drug: PF-06865571

First Posted Date: 2018-07-20

Last Posted Date: 2019-03-28

Lead Sponsor: Pfizer

Target Recruit Count: 18

Registration Number: NCT03593707

Locations: 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium

A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)

Phase 3

Completed

Conditions: Hemophilia B
Hemophilia A

Interventions: Drug: Standard of Care FIX Replacement therapy
Drug: Standard of Care FVIII Replacement therapy

First Posted Date: 2018-07-16

Last Posted Date: 2025-04-24

Lead Sponsor: Pfizer

Target Recruit Count: 213

Registration Number: NCT03587116

Locations: 🇮🇹
UOC Medicina Interna - Malattie Emorragiche e Trombotiche, Napoli, Naples, Italy
🇺🇸
Stanford Health Care, Stanford, California, United States
🇧🇪
Cliniques universitaires Saint-Luc/Unité d'Hématology et Hémostase, Brussels, Belgium

and more 72 locations

A 6-week Study to Evaluate the Safety and Efficacy of Quillichew ERCT in 4-5 Year Old Children With ADHD.

Phase 4

Withdrawn

Conditions: Attention Deficit Hyperactivity Disorder
Attention Deficit Hyperactivity Disorder (ADHD)

Interventions: Drug: Placebo
Drug: methylphenidate HCl ERCT

First Posted Date: 2018-07-09

Last Posted Date: 2018-11-01

Lead Sponsor: Pfizer

Registration Number: NCT03580005

Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria

Phase 3

Terminated

Conditions: Serious Bacterial Infection

Interventions: Combination Product: ATM-AVI
Drug: BAT

First Posted Date: 2018-07-09

Last Posted Date: 2024-02-02

Lead Sponsor: Pfizer

Target Recruit Count: 15

Registration Number: NCT03580044

Locations: 🇨🇳
The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China
🇨🇳
Hunan Province People's Hospital, Changsha, Hunan, China
🇨🇳
The First Hospital of Kunming, Kunming, China

and more 38 locations

Evaluation Of Clostridium Difficile Vaccine Lot Consistency In Healthy Adults 65 To 85 Years Of Age

Phase 3

Completed

Conditions: Clostridium Difficile Associated Disease

Interventions: Biological: Clostridium difficile vaccine
Biological: placebo

First Posted Date: 2018-07-06

Last Posted Date: 2023-01-19

Lead Sponsor: Pfizer

Target Recruit Count: 1317

Registration Number: NCT03579459

Locations: 🇺🇸
Amici Clinical Research, Raritan, New Jersey, United States
🇺🇸
Coastal Clinical Research, Inc., Mobile, Alabama, United States
🇺🇸
Paradigm Clinical Research Centers, Inc., Redding, California, United States

and more 20 locations

Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis

Phase 3

Completed

Conditions: Dermatitis, Atopic

Interventions: Drug: PF-04965842 200 mg
Drug: PF-04965842 100 mg
Drug: Placebo

First Posted Date: 2018-07-03

Last Posted Date: 2020-04-21

Lead Sponsor: Pfizer

Target Recruit Count: 391

Registration Number: NCT03575871

Locations: 🇨🇦
Diex Recherche Sherbrooke Inc., Sherbrooke, Quebec, Canada
🇺🇸
The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
🇺🇸
Center for Clinical Studies, LTD. LLP, Houston, Texas, United States

and more 110 locations

A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Infants and Young Children

Phase 3

Completed

Conditions: Pneumococcal Infections
Pneumococcal Conjugate Vaccine

Interventions: Biological: 13vPnC
Biological: Hib

First Posted Date: 2018-07-02

Last Posted Date: 2024-11-05

Lead Sponsor: Pfizer

Target Recruit Count: 936

Registration Number: NCT03574389

Locations: 🇨🇳
Huaiyin District Center for Disease Prevention and Control, Huaian, Jiangsu, China
🇨🇳
Guanyun County Disease Control and Prevention, Lianyungang, Jiangsu, China

Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031

Phase 3

Terminated

Conditions: Sickle Cell Disease

Interventions: Drug: Voxelotor

First Posted Date: 2018-06-29

Last Posted Date: 2024-11-26

Lead Sponsor: Pfizer

Target Recruit Count: 179

Registration Number: NCT03573882

Locations: 🇺🇸
Children's Healthcare of Atlanta at Hughes Spalding, Atlanta, Georgia, United States
🇺🇸
University of Illinois Hospital and Health Science System, Chicago, Illinois, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 62 locations

A Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults

Phase 2

Terminated

Conditions: Respiratory Tract Infection

Interventions: Biological: Formulation A
Biological: Placebo
Biological: Formulation B
Biological: Formulation C

First Posted Date: 2018-06-28

Last Posted Date: 2021-08-26

Lead Sponsor: Pfizer

Target Recruit Count: 317

Registration Number: NCT03572062

Locations: 🇦🇺
Doctors of Ivanhoe, Ivanhoe, Victoria, Australia
🇦🇺
Australian Clinical Research Network, Maroubra, New South Wales, Australia
🇦🇺
Holdsworth House Medical Practice, Sydney, New South Wales, Australia

and more 13 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy